Nasus Pharma, a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, is headquartered in Tel Aviv, Israel, and trades on NYSE American under the ticker NSRX. Brendan O'Grady serves as Chief Executive Officer of Nasus Pharma.

The company's lead program, NS002, is an investigational intranasal epinephrine powder for the treatment of anaphylaxis, positioned as a needle-free alternative to EpiPen. NS002 is Nasus Pharma's lead product candidate for Type I allergic reactions, including anaphylaxis.

Highlights

  • NS002 is Nasus Pharma's lead product candidate for Type I allergic reactions, including anaphylaxis.
  • The FDA cleared the company's IND application for NS002.
  • Nasus Pharma's pivotal study is expected in the fourth quarter of 2026.
  • Topline data are expected in the first quarter of 2027.
  • Nasus Pharma is headquartered in Tel Aviv, Israel.

What Changed

The FDA has cleared Nasus Pharma's IND application for NS002, allowing the company to proceed toward a pivotal study expected in the fourth quarter of 2026. Topline data from that study are expected in the first quarter of 2027.

Who Is Affected

For traders following the stock, the clinical design matters: the study compares self-administration of NS002 to administration by a health care professional. If you hold a position in Nasus Pharma, this design will determine whether NS002 can be self-administered outside a clinical setting.

What To Watch Next

Nasus Pharma filed its annual report on March 25, 2026. Investor inquiries are handled by Mike Moyer, who serves as Investor Contact at LifeSci Advisors. Traders watching for catalysts should note the topline data readout expected in the first quarter of 2027.